A Timcast IRL video carries the title "Side Effects of Ozempic Include Blindness and STOMACH PARALYSIS," presenting both as settled, confirmed effects of the diabetes and weight-loss drug. The regulatory record does not support that framing. Neither blindness nor stomach paralysis appears on the FDA-approved label as a confirmed side effect of Ozempic.
Start with what the video gets right, because the concern is not invented. The vision-loss condition at issue, non-arteritic anterior ischemic optic neuropathy, or NAION, is the subject of real research. A July 2024 study published in JAMA Ophthalmology described an association between semaglutide, the active ingredient in Ozempic, and NAION [1]. There is also active litigation over the drug's gastrointestinal effects [2]. A patient who has heard about either is not reacting to nothing.
The error is in the leap from association-under-study to confirmed side effect. NAION is a studied association, not a formally labeled effect of the drug [1]. It is not on the official FDA label. A researcher noting a statistical link and a regulator adding a warning are two different events, and only the second one is what the video's title claims has happened.
The stomach paralysis claim rests on a similar slide. Gastroparesis, the clinical term for stomach paralysis, is not FDA-listed as caused by Ozempic [1]. What the label actually says is that Ozempic is not recommended in patients with severe gastroparesis [2]. That is a contraindication caveat, a caution about giving the drug to people who already have the condition, which is close to the opposite of a finding that the drug causes it.
The FDA has updated the drug's warnings, which is worth stating plainly rather than leaving as a gap. Ileus, a blockage of the intestine, was added to the Ozempic warnings in September 2023, and a broader gastrointestinal warning update followed in January 2025 [1][2]. Those are the real, documented regulatory actions. None of them amounts to a label entry confirming that Ozempic causes blindness or stomach paralysis.
The distinction is not academic for the people watching. Ozempic manages blood sugar for diabetics and is prescribed for weight loss. A viewer who takes the title at face value learns that a drug they may depend on has two confirmed, terrifying outcomes, when the accurate version is that one condition is an association under active study and the other is a caution about pre-existing illness. The gap between those two accounts is the gap between an informed decision and a scared one.
Our verdict on the claim that these "include" confirmed Ozempic side effects is that it is misleading. The signals are real and under study; the certainty the title assigns them is not.
